Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer

Recruiting Phase 2 Interventional Study
Resectable Intrahepatic Cholangiocarcinoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
62 (estimated)
Sponsor
Center Eugene Marquis · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Treatment of intrahepatic cholangiocarcinoma (ICC) remains difficult. Many patients have unresectable tumors, and survival after resection was only slightly improved with the use of adjuvant capecitabine. One of the major prognostic factors is the resection margin, patients with invaded (R1) or narrow (\<5mm) margins having a higher risk of recurrence. Selective Internal Radiation Therapy (SIRT) …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Age \> 18 years-old, 2. ECOG Performance Status \<2, 3. Histologically-proven ICC, 4. No previous treatment for ICC, 5. Tumour deemed resectable by a hepatobiliary surgeon, validated by a Surgical Review Board, 6. Significant risk of close margins, defined as: 1. Resectio…
Contacts

Marion Trochet

02 99 25 31 65

m.trochet@rennes.unicancer.fr

CONTACT

Valérie Jolaine

02 99 25 30 36

v.jolaine@rennes.unicancer.fr

CONTACT